Castor collaborates with Microsoft to bring Practical AI to clinical trials.

February 8th, 2024 by

NEW YORK, N.Y. – February 8, 2024 – Today, Castor announced its collaboration with Microsoft to use Microsoft Azure to bring modern artificial intelligence (AI) to clinical trials. Offering a modular, patient-centric clinical trial platform, Castor is focused on developing technology that reduces burden for patients, sponsors, and study teams. 

As a part of this announcement, the company is releasing its first in a line of Practical AI features to all its users in public Beta. 

“We see an opportunity for AI and automation to significantly reduce the burden of day-to-day clinical trial activities for site staff, clinical research associates and data managers. On the patient side, we envision Large Language Models (LLMs) helping with patient education and real-time support” said Dr. Derk Arts, MD PhD, CEO & Founder of Castor. “Our work with Microsoft Azure is a critical step to bring these practical capabilities to production in a secure and responsible manner.”

Over the last 18 months, Castor has advanced an AI roadmap in collaboration with Microsoft using Azure. The Beta release of Castor’s first Practical AI feature will be available to the company’s 147,000+ users. The feature will help Castor users develop their studies faster by simplifying complex tasks in the study build process. In November 2023, Castor demonstrated the potential future-state of its Practical AI with an AI Demo at CNS Summit. The company won the Award for best AI Demo out of 30 applicants. The award was handed out by judges Junaid Bajwa (Chief Medical Scientist – Microsoft) and MaryAnne Rizk (Board member – Netramark). 

“Castor’s vision is to create a future where all data contributes directly to discovering cures to the world’s diseases.  Microsoft is pleased to support this vision by providing an industry-leading data and AI platform that is being used by Castor as they work to improve the clinical trial process.” Junaid Bajwa – Chief Medical Scientist of Microsoft Research.

Castor chose Azure to launch its AI solutions because Azure offers an enterprise-grade environment for developing and deploying cutting-edge capabilities, ensuring any data used for training is secure, and production deployments are monitored and reliable. 

“Large Language Models (LLMs) can help improve patient education and support, aiding in the optimization of study participant retention,” said Dr. Arts. “The essence of AI is not just about automating tasks, it’s letting humans be human. By reducing repetitive and time-consuming tasks, we give back precious time to our users; time that can be spent focusing on patients and participants. That is the real promise, the practical promise of AI.” 

Castor EDC, ePRO, eConsent

About Castor

Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s modular platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, eConsent, eCOA and real-world data capture. 

Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide. 

For more information, follow us on LinkedIn:

https://www.linkedin.com/company/castoredc

https://www.linkedin.com/in/derkarts/

Contact
Laura McLoughlin
Castor
[email protected]

Comments closed

Castor Steps Up to Preserve Critical Research Amid NIH Funding Cuts

February 14th, 2025 by

In response to the recent National Institutes of Health (NIH) policy reducing indirect cost reimbursements to 15%, Castor has announced free access to its flagship clinical trial technology platform for any federally funded studies in the United States, via the Castor for Impact Program. This significant cut from previous reimbursement rates has placed many research institutions under immense financial strain, generating concern that essential scientific work could grind to a halt.

The ripple effects of this policy shift have already touched both new and ongoing grants. Universities and academic medical centers depend on these overhead allocations to sustain vital research infrastructure, such as administrative support and technology solutions. With indirect costs now substantially reduced, projects face heightened risk of operational setbacks or, in some cases, cessation.

Recognizing the urgency of the situation, Castor is offering its platform at no cost to help researchers maintain data integrity, regulatory compliance, and efficient workflows without draining their already limited budgets.

Dr. Derk Arts, CEO and Founder of Castor said,

“With so many projects funded under the previous indirect cost structures, researchers are suddenly dealing with unexpected financial hurdles.

We believe that impactful discoveries should not fall victim to shifting budgetary policies. Making our platform free for federally funded studies through the Castor for Impact Program is a direct response to the challenges faced by researchers nationwide.”

The Castor for Impact initiative aims to remove barriers for critical research across a range of therapeutic areas and institutions. By providing secure data capture, rapid deployment, and automated study management features, the program allows investigators to maintain focus on scientific innovation rather than administrative tasks. Furthermore, the user-friendly setup requires minimal IT support, allowing studies to launch quickly and continue with minimal disruption.

Eligible investigators can visit the Castor for Impact webpage to complete a straightforward online enrollment process. This streamlined approach helps protect ongoing research from setbacks brought on by funding uncertainty. As the landscape of federal research support continues to evolve, Castor’s expanded initiative offers a reliable safeguard—ensuring that scientists can keep driving medical progress forward.

Get free access now

Comments closed

Castor Bolsters Remote Study Engagement with Streamlined Participant Workflow

June 5th, 2025 by

Raleigh, NC – May 23, 2025 – Castor, a leading provider of clinical trial technology, announced today a significant update to its eConsent platform, making a one-time password (OTP) login the default for all eConsent implementations. This change, coupled with a seamless participant journey, addresses common hurdles in remote clinical trial participation, aiming to reduce drop-off rates and improve data capture efficiency.

Traditional eConsent systems often introduce unnecessary friction by requiring participants to create accounts, verify emails, and set passwords before accessing screening or consent forms. This multi-step process frequently leads to participant disengagement, a critical challenge in remote and decentralized clinical trials.

What Castor Changed:

Castor’s updated eConsent workflow now defaults to OTP login, eliminating the need for account setup or password creation. Participants receive a single-use code, allowing immediate access to the study workflow. This means:

“This isn’t about adding a ‘shiny feature.’ It’s about fixing a fundamentally broken process that most vendors still get wrong,” stated Lisa Charlton, Chief Product Officer at Castor. “Our focus is on creating an intuitive, consumer-grade experience that aligns with how people interact with technology in their daily lives, while maintaining compliance and security.”

Why This Matters for Clinical Trials:

This streamlined approach directly impacts critical study metrics:

Supporting Data:

In a recent real-world evidence study leveraging this OTP-enabled workflow, Castor observed:

This enhanced workflow directly supports fully remote, direct-to-patient study designs, enabling seamless transitions from initial interest expression through screening and consent, all from the participant’s own device.

Compliance and Security:

OTP login is designed to be secure, 21 CFR Part 11 compliant, and fully auditable. It reduces the risk associated with unmanaged credentials by eliminating the need for participants to create and remember complex passwords, thereby enhancing overall security posture.

The Castor Standard:

One-time password login is now standard for all Castor eConsent implementations. This decision reflects Castor’s commitment to optimizing clinical workflows for participants, rather than imposing technological hurdles.

🎥 See the OTP flow in action in our 2025 Product Spotlight webinar.

Comments closed

Castor Supports LLS in Study to Improve Blood Testing

May 1st, 2025 by

A pro bono partnership using AI to make blood sample collection easier for patients

Castor is proud to announce a pro bono collaboration with the Leukemia & Lymphoma Society (LLS) on a groundbreaking study designed to improve the way blood samples are collected and monitored for patients with blood disorders. The initiative aims to validate a more accessible, less invasive method for Complete Blood Count (CBC) testing using the Tasso at-home blood collection device.

By leveraging Castor’s AI-powered clinical trial platform, the LLS study team was able to rapidly build and deploy the study protocol—accelerating study launch timelines while maintaining quality and compliance through human-supervised QA processes.

“At Castor, we believe AI should do more than automate—it should empower,” said Derk Arts, CEO of Castor Research Inc.

“This collaboration with LLS demonstrates how technology can improve the research process while putting patients first.”

The study evaluates the performance of the Tasso device versus traditional venipuncture to determine whether a patient-friendly, remote sampling option can be adopted for ongoing monitoring of blood cancers such as leukemia and lymphoma. The goal is to reduce patient burden and make routine testing easier—especially for those who face geographic, physical, or psychological barriers to accessing care.

LLS, the world’s largest voluntary health organization dedicated to fighting blood cancers, views this partnership as a significant step forward in modernizing patient care.

Ashley Yocum, PhD Executive Research Strategy Lead, Beat AML Master Trial, Leukemia & Lymphoma Society said:

“We are excited to work with Castor and leverage their platform to explore less invasive options for patients living with blood disorders…

This partnership helps advance our mission to deliver better care and more compassionate solutions for those who need them most.”

This partnership reflects Castor’s long-standing commitment to accelerating clinical research through technology—while ensuring that innovation serves both science and society.

This partnership is one of many ways Castor is working to make smarter, more compassionate research possible for all. Whether it’s enabling patient-friendly innovation through AI or helping underfunded researchers stay afloat, our mission remains the same: to accelerate research that improves lives.

👉 Read how we’re helping preserve critical research in the face of NIH funding cuts through Castor Essentials: Castor Steps Up to Preserve Critical Research

About Castor Research Inc.

Castor is a leading provider of AI-powered clinical trial technology that accelerates study design, streamlines data capture, and enhances patient engagement. From remote trials to real-world evidence and device studies, Castor’s platform enables sponsors and researchers to launch studies faster, collect higher-quality data, and reduce operational burden. Headquartered in the U.S. and the Netherlands, Castor supports leading academic institutions, emerging biotechs, and global pharmaceutical companies in conducting smarter, more accessible research.

About the Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society (LLS) is the world’s largest voluntary health organization dedicated to funding blood cancer research, education, and patient services. LLS’s mission is to cure leukemia, lymphoma, Hodgkin’s disease, and myeloma, and improve the quality of life of patients and their families.

Media Contact:
Kevin Thornton, Director of Marketing, Castor
[email protected] | 919-579-8690

Comments closed

Castor Launches Scalable Patient Enrollment and eConsent Platform to Increase Patient Access and Reduce Recruitment Timelines

July 28th, 2021 by

HOBOKEN, N.J.–(BUSINESS WIRE)–Castor, a leading provider of clinical trial technology to democratize clinical research, today announced a full patient onboarding experience to enhance patient enrollment, from recruitment to first study visit.

The current patient enrollment process for clinical trials can be time-consuming and confusing. Building on Castor’s eConsent solution, patients can now experience a seamless transition on their journey from recruitment to screening, consent, and enrollment. A transparent, efficient enrollment experience lets participants know what is expected of them in the study – the better they understand their commitments, the higher study engagement, and lower dropout rates.

​​”When designing our DTx study with Castor, we knew creating a patient-centric and simple process was critical,” said Karina Palafox, Director, Clinical Data Management at Click Therapeutics. “Thanks to Castor, we were able to easily integrate eConsent with ePRO, and EDC for our study needs; we believe Castor’s approach will help lead to trial success and account for patient adoption of our approach to decentralized clinical trials and Click Therapeutics study technology.”

Castor’s patient-focused onboarding process is completed entirely through Castor’s DCT platform, to support both participants and investigators remotely or on-site. An all-in-one screening and enrollment solution designed around the patient experience, Castor’s eConsent solution can:

  • Recruit patients with a dedicated and customized study enrollment web portal
  • Pre-screen patients to ensure patients meet study criteria
  • Remotely or onsite consent patients with video virtual visit capabilities and digital signatures
  • Upon consent, randomize patients and collect study data with Castor’s Clinical Data Management Platform (EDC/CDMS)

“About one-third of patients drop out of clinical trials due to a lack of patient-centric design. Castor’s cloud-based platform improves the early study experience of investigators and patients by decentralizing clinical trials. We have seen by simplifying participant enrollment, our study sponsors are seeing improved retention in trials and reduced recruitment timelines,” said Derk Arts, Ph.D., M.D., CEO & Founder, Castor. “We are at the forefront of digital health transformation, and our scalable clinical trial solutions can accelerate drug development and improve patient engagement.”

To Learn More — Register for Castor & Lightship’s webinar: “It’s a matter of choice: Hybrid eConsent for On-Site or Remote Patient Enrollment.”

About Castor

Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, consent, and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide. For more information, visit castoredc.com. Follow us on Twitter at @castor.

Contacts

Media
Kimberly Ha
KKH Advisors
[email protected]

Comments closed

Castor Raises $45M Series B to Modernize the Clinical Trial Process and Maximize the Impact of Research Data on Patient Lives

July 14th, 2021 by

HOBOKEN, N.J. — Castor, a leading provider of clinical trial software, announced today the closing of a $45 million Series B financing round, bringing the company’s total funding to $65 million.

The round, led by Eight Roads Ventures and F-Prime Capital with participation from existing investors Two Sigma Ventures and Inkef Capital, will fuel continued product development with a particular focus on scaling direct-to-patient trials globally.

“Castor was created with the mission to help researchers globally conduct more effective clinical trials while improving the patient experience,” said Derk Arts, M.D., CEO & Founder of Castor. “Prioritizing the patient and site user experience is particularly important today, when COVID-19 has fundamentally changed the nature of clinical trials.”

Most clinical trials today require a long set-up time and are conducted at brick-and-mortar research sites which make trial participation inconvenient for patients and leave researchers in the dark about patient data in-between site visits. As a result, 38.7% of terminated trials being halted due to slow enrollment¹, and the cost to develop a drug has more than doubled in the last decade to $2.7 billion across a 12-year timeline².

Castor offers a modern, self-service clinical research platform, which enables every researcher worldwide to design studies and integrate data from any source in real-time. Patients can enroll themselves in trials, consent and share their data online or via a mobile app, allowing the industry to seamlessly shift to decentralized clinical trials (DCT). These capabilities have been critical during the COVID-19 pandemic as Castor’s customers were able to quickly change their study designs and incorporate increased collection of remote patient data.

Since 2014, Castor has supported over 7,500 studies in more than 90 countries. Over the last 12 months, the company more than doubled in size and it has worked with customers such as the World Health Organization, which used Castor for its Solidarity Trial, and landed contracts with over 20 top-tier digital therapeutics companies and signed its first top 5 pharmaceutical company.

“COVID-19 forced the industry to change and required agility and customer centricity that Castor was uniquely positioned to deliver,” said Michael Treskow, Partner at Eight Roads Ventures.

“We believe that Castor’s visionary approach will significantly improve the quality of clinical research and we are excited to support Derk and the team as they continue to transform the industry on a global scale,” said Alex Pasteur, Partner at F-Prime Capital.

1. Williams RJ, et al. Terminated Trials in the ClinicalTrials.gov Results Database: evaluation of availability of primary outcome data and reasons for termination. PLoS One. 2015;10(5):e0127242.

2. J. DiMasi, et al. Innovation in the pharmaceutical industry: New estimates of R&D costs, Journal of Health Economics, Volume 47, 2016, Pages 20-33

About Eight Roads Ventures

Eight Roads Ventures is a global venture capital firm managing $7bn of assets across offices in the UK, China, India, Japan, and the US. Our 50-year history of investing includes partnerships with over 300 companies such as Alibaba, Appsflyer, BlackDuck, Cazoo, Chewy, Devoted Health, Flywire, Icertis, iPipeline, Kensho, Letgo, Made.com, Neo4j, Nuance, Paidy, Ping Identity, Pony.ai, Toast, Wallapop, WuXi PharmaTech, and Xoom.

About F-Prime Capital

F-Prime Capital is a global venture capital firm investing in healthcare and technology. For the past 50 years, our independent venture capital group has had the privilege of backing great entrepreneurs building groundbreaking companies.

With over $2 billion dollars under management and a global portfolio of more than 200 companies, we champion those dedicated to creating positive change in the world. In healthcare, we focus on therapeutics, medtech and health IT & services in a stage-agnostic fashion. Our healthcare fund has created or co-created 23 companies including Denali, Beam, Innovent, Orchard and Sana and has helped build many others including Blueprint Medicines, Iora Health, PatientPing, Devoted and Ultragenyx. F-Prime portfolio companies have seen more than 28 products and drugs approved by regulatory agencies worldwide. Our team of investors, engineers, doctors and scientists is committed to bringing the insight, domain expertise and relationships required to help our companies make a transformational impact.

F-Prime is headquartered in Cambridge, MA, with offices in London, UK and San Francisco, CA.

Contacts

Media
Kimberly Ha
KKH Advisors
[email protected]

Read more on TechCrunch and Fierce Biotech.

Comments closed

Castor Launches Real-World Evidence Offering to Simplify Post-Marketing Clinical Trials

November 10th, 2022 by

NEW YORK, N.Y. – November 1, 2022 – Castor, a leading provider of decentralized and hybrid clinical trial technology solutions, today announced a new offering to simplify post-marketing clinical trials. By extending global reach, integrating real-world data (RWD), and automating trial processes, Castor’s latest offering can reduce trial costs by 30% and deployment timelines to only 4 weeks on average.

“Real-world evidence has the potential to transform evidence based medicine, by generating a body of evidence that provides a much more accurate view on what cure is best for each individual patient, through including a more diverse range of patients and in everyday settings,” said CEO and co-founder Derk Arts, M.D, Ph.D. “Our latest offering simplifies the creation of RWE into clinical trials and supports life science companies in their pursuit of drug discovery and development goals.”

Castor RWE addresses common PMCT challenges by easily integrating real-world data sources such as patient-reported outcomes and wearables to increase patient access and retention as well as data quality and compliance. The offering, Castor Real-World Evidence (RWE), provides integrated technology and services to accelerate the collection of RWD for post-marketing clinical trials (PMCT), enabling life science companies to meet regulatory and payer requirements efficiently.

The offering includes pre-configured modules for patient recruitment, eligibility screening, enrollment, data capture, and participant engagement. This comprehensive approach helps sponsors uncover valuable insights into drug performance in real-world settings, while expanding access to global trial populations.

“We are committed to supporting life science companies in all aspects of their clinical trials, from early drug discovery to post-marketing studies,” said Castor CPTO Andy Sadler.“Castor RWE is a natural extension of our platform, and we are excited to provide this solution to our clients.”

To learn more about Castor RWE visit https://www.castoredc.com/real-world-evidence/.

About Castor

Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform, Castor’s modular platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to monitoring, and improving the quality, security, and reusability of data for researchers worldwide. For more information, visit www.castoredc.com. Follow Castor on LinkedIn or Twitter.

Contacts

Castor
Dana Perotti, [email protected]

Media
KKH Advisors
Kimberly Ha, [email protected]

Comments closed

Persbericht: Nederlandse health-tech startup wint Europese aanbesteding LUMC voor data management systeem

October 17th, 2018 by

Amsterdam, Netherlands – 17 Oktober, 2018

De Nederlandse health-tech startup Castor EDC, een electronic data capture-platform voor medisch onderzoek, heeft een Europese aanbesteding gewonnen bij het Leids Universitair Medisch Centrum (LUMC). Met het platform van Castor EDC kunnen de onderzoekers van het LUMC in een paar stappen een klinische dataverzameling voor onderzoek opstellen en
uitvoeren.

Eenvoudig onderzoeksdata verzamelen en delen
Met Castor EDC kunnen onderzoekers eenvoudig onderzoeksdata verzamelen, standaardiseren en delen. Alle klinisch onderzoekers in het LUMC krijgen hiermee toegang tot het Castor EDC-platform. Het platform maakt tevens een koppeling met het Medical Intelligence platform dat door het LUMC is opgezet, waarbij data uit onder andere het EPD (HiX van Chipsoft) gebruikt kunnen worden voor klinisch wetenschappelijk onderzoek.

HL7 FHIR en analyse-omgeving
Dankzij een koppeling van Castor EDC kunnen gepseudonimiseerde patiëntgegevens via een veilige, versleutelde verbinding, conform de HL7 FHIR-standaard, beschikbaar worden gesteld in het onderzoeksplatform ten bate van klinisch onderzoek. Hiermee besparen de onderzoekers veel tijd, omdat gegevens uit patiëntendossiers niet meer handmatig hoeven worden overgenomen.

Zonder uitleg aan de slag
De implementatie van Castor EDC in het LUMC wordt uitgevoerd in samenwerking met Beter Healthcare, Furore en Firely. “Met ons datamanagementsysteem kunnen de onderzoekers van het LUMC zeer laagdrempelig, veilig en vele malen sneller dan voorheen klinisch onderzoek uitvoeren,” aldus Derk Arts, oprichter en CEO van Castor EDC. “In principe kunnen de onderzoekers van het LUMC binnen enkele uren en zonder nadere uitleg een studie bouwen in hun Castor-omgeving, maar toch kiezen wij ervoor om zeven trainingen te beleggen. ”

Over Castor EDC
Castor EDC heeft één doel voor ogen: medisch onderzoek slimmer en efficiënter maken met gebruiksvriendelijke technologie. Met 30 mannen en vrouwen wordt elke dag gewerkt aan software tools die het voor onderzoekers en patiënten wereldwijd mogelijk maakt meer te halen uit alle tijd en geld die in medisch onderzoek wordt gestoken. Opgericht in 2012, telt Castor EDC intussen 2.800 onderzoeken, 23.000 gebruikers en 80 instellingen zoals het AMC, Radboudumc en King’s College Hospital in Londen (VK) onder zijn afnemers.

Over de oprichter, Derk Arts
Oprichter en CEO is de Derk Arts (MD, PhD, 32 jaar). Hij richtte het bedrijf op tijdens zijn PhD in het
AMC in Amsterdam. Vorig jaar heeft het bedrijf 1,1 miljoen euro subsidie ontvangen vanuit Horizon
2020, het innovatieprogramma van de Europese Commissie voor MKB-bedrijven.

No comments yet

Castor Delivers Strong Finish to 2021, Continues Expansion into US Market

December 16th, 2021 by

HOBOKEN, NJ — December 15, 2021 – Castor, a leading provider of decentralized and hybrid clinical trial solutions, today announced transformative growth with anticipated topline acceleration driven by the company’s momentous US market expansion and focus on life sciences enterprise sales. In 2021, the company reported 125% YoY growth,  more than doubled its workforce, launched New York operations, and powered more than 2,500 studies across the globe.

Life sciences companies, digital health innovators, and researchers trust Castor to power their studies, evidenced by a 98% customer satisfaction rating and an increased customer base of 39% from 2020. Since 2014, Castor has supported over 8,500 studies across 100+ disease indications and reached over 3 million participants across more than 90 countries. 

2021 milestones for Castor include:

“It can be difficult to find fit-for-purpose trial solutions for studies that vary in size, complexity and face different budget constraints. We have partnered with Castor because their solution is easy-to-use and easily scales across varying regulatory environments,” said David Shah,  Manager, Clinical Data Management of Ethicon, a Johnson & Johnson company. “Ultimately, Castor provides us with the ability to set realistic timelines and deliver positive clinical trial experience for both internal, sponsor, and external, participants and sites, users.”

In 2021, Castor continued to deliver on its mission of democratizing global research. During the COVID-19 pandemic, Castor donated its technology and ground-breaking clinical research solutions to more than 300 COVID-19 studies across 40 countries. The company provided free access to its CDMS/eSource and decentralized clinical trial (DCT) solutions for COVID-19 studies to empower researchers, and remove barriers to save lives. 

Castor-supported COVID-19 studies include:

“2021 was a year of transformative growth, and our technology solutions powered the world’s leading COVID-19 projects and  transformative studies  into ‘digital’ cures for patients,” said Derk Arts, CEO and Founder of Castor. “We will continue to innovate to enable researchers to conduct more effective clinical trials while improving the patient experience, to bring new therapies to patients faster.”

Learn more about Castor’s expanding team here. If you’re interested in joining a passionate and collaborative organization bringing clinical trials into the 21st century, Castor is hiring.

About Castor

Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, eConsent, and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide. For more information, visit www.castoredc.com. Follow us on Twitter at @castor.

Contacts

Castor
Dana Perotti
[email protected]

Media
Kimberly Ha
KKH Advisors
[email protected]

Comments closed

Castor Expands Executive Leadership Team to Scale Clinical Trial Platform Technology

September 14th, 2021 by

HOBOKEN, N.J.– September 15, 2021 — Castor, a leading provider of clinical trial technology to democratize clinical research, announced two executive appointments to accelerate the company’s growth and impact on the industry.  Kimberly Tableman as Chief Clinical Development Officer (CCDO) and Anna Wozniak as Chief Financial & Development Officer (CFDO).

Castor’s new CCDO, Kimberly Tableman, brings more than 23 years of experience in clinical development and technology. Over the past decade, she has focused on applying digital health technologies to reimagine the patient journey. She was most recently CEO at Medicine X, and co-founder at Rabble Health, where she led the development and beta launch of a patient engagement platform to serve Oncology patients. Prior to Medicine X, Kimberly held senior roles at GlaxoSmithKline (GSK), including Head of Patient Engagement and Head of Digital Clinical Trials. She has also worked at Pfizer, and began her career in management consulting at Cap Gemini Ernst & Young. 

 “I am passionately committed to serving diverse patients through products that facilitate a positive research journey and increase accessibility to precision-medicine treatments,” said Tableman. “I am thrilled to be a part of the Castor team and to work alongside peers who are equally dedicated to making patient-centric trials a reality”. 

Anna Wozniak, Castor’s new CFDO, brings more than 14 years of life sciences experience, building and scaling businesses through her focus on strategy, leadership, and driving execution. Anna was previously Executive Vice President Strategy and Development at BC Platforms, a personalized medicine company, driving growth post-Series A through Series C. Before joining BC Platforms, she held various finance and strategy roles at Syngenta. 

“Castor’s technology-first approach to patient-centric research is primed for continued growth given the significant market need for digital transformation,” said Wozniak.  “My experience scaling businesses and accelerating growth has led me to Castor – to deliver on the promise of enabling faster, smarter, clinical research.” 

“Castor has grown tremendously in the past year, and with Anna and Kimberly- we add two strong, strategic leaders to help guide us during this phase of our growth,” said Derk Arts M.D., Ph.D., CEO & Founder, Castor. “I am delighted to welcome Anna and Kimberly to Castor, both highly skilled professionals with decades of experience within these critical corporate operational areas to ensure we can continue to successfully help researchers conduct more effective clinical trials on a global scale while improving the patient experience.”

Learn more about Castor’s expanding leadership team here. And, if you’re interested in joining a passionate and collaborative organization bringing clinical trials into the 21st century, Castor is hiring.

About Castor

Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, consent, and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide. For more information, visit castoredc.com. Follow us on Twitter at @castor.

Contacts

Castor
Dana Perotti
[email protected]

Media
Kimberly Ha
KKH Advisors
[email protected]

Comments closed

Castor Leads Next-Gen Clinical Trials that Support Digital Therapeutics

August 18th, 2021 by

– Castor is supporting the next generation of digital therapeutics that can improve patient lives with
disease-modifying potential.
– Castor has worked with more than 30 DTx companies.


HOBOKEN, N.J.–(BUSINESS WIRE)– Castor, a leading provider of clinical trial technology to democratize clinical research, announced that it is powering the next generation of clinical trials with more than 30 digital therapeutics (DTx) studies ongoing. A new class of therapeutics is rapidly advancing medicine: digital therapeutics or “DTx”. These digital treatments have disease-modifying properties that are effective for a wide range of debilitating and deadly diseases.

Castor is supporting this fast-growing segment in clinical trials, as DTx is expected to have continued exponential growth with a CAGR of 30%, according to a recent industry report. Castor helps DTx companies overcome many of the unique challenges they face in clinical trials, from recruitment, screening, and informed consent to data capture – while integrating sensor and app data seamlessly through an open API.


MedRhythms, a digital therapeutics company based in Portland, Maine, uses sensors, music, and software to build evidence-based, neurologic interventions to measure and improve walking. Intended to be a rehabilitative device for walking improvement, MedRhythms’ first product intends to serve chronic stroke patients with walking difficulties and seeks to improve the speed and quality of walking. MedRhythms selected Castor as their Clinical Data Platform, citing Castor’s transparency with cost predictions, user-friendliness, and the ability to try a full version of Castor
before buying.

“Castor’s solutions were easy to navigate and intuitive to use, which is why we were interested in working with them,” said MedRhythms CEO & Founder, Brian Harris. “They were able to accommodate the amount of data from our multi-site randomized controlled trial and our sites have expressed how much they have enjoyed using Castor as well.”

For MedRhythms, even monitoring, often one of the most cumbersome trial activities, turned into a seamless process since sites quickly grasped Castor’s user interface. With Castor, study teams found it easy to log in, add a participant and randomize with Castor’s built-in randomization tool.

“Castor is powering the future of medicine, a new category of prescription digital therapeutics at the forefront of revolutionizing healthcare,” said Derk Arts, Ph.D., M.D., CEO & Founder, Castor. “Healthcare is slowly moving away from traditional therapies or a physical medical device, and instead adopting software as a medical device (SaMD). This shift changes everything about how we need to approach a novel clinical study in digital therapeutics. We look forward to powering additional studies with Castor’s DCT and Hybrid Trial platform to advance the field of digital medicine.”

Register for DTx East on September 28th to hear how Castor is “Reshaping the Future of Clinical Trials for Digital Therapeutics.”

About Castor

Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, consent, and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide. For more information, visit www.castoredc.com. Follow us on Twitter at @castor.


Contacts
Media
Kimberly Ha
KKH Advisors
[email protected]

Comments closed

Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

February 2nd, 2022 by

NEW YORK, NY — February 2, 2022 – Castor, a leading provider of decentralized and hybrid clinical trial solutions, today announced the official launch of its CRO Partnership program. Designed to support clinical research organizations (CROs), the program provides the technical capabilities, operational training and commercial resources required to successfully deliver traditional, hybrid and decentralized clinical programs for trial sponsors.

“Castor allows us to add value to our service offerings and deliver innovative technology solutions with minimal upfront investment,” said Kathleen Marshall, President and Founder of MAXIS LLC. “As a partner, we’ve been able to reduce time spent building and managing studies, streamline data collection, increase access and reduce the burden on sites and patients.”

The success of clinical trials relies heavily on the eClinical solutions that support them, making it imperative to implement a flexible, technology-enabled approach. Castor’s modular eClinical platform with self-service functionality is lightweight, easy to use, easy to deploy and easily integrated with established systems. Castor’s out-of-the-box solutions reduce the number of tools needed to execute a clinical trial while also minimizing the need for add-on services when designing proposals for sponsors. As a Castor partner, CROs can deliver studies of varying complexity for more sponsors, with the necessary flexibility and speed to quickly adapt, without disrupted timelines or expanded budgets.

“We look forward to launching our CRO partnership program, as our platform offers unprecedented scalability, enabling our CRO partners to run patient centric trials as their core business, instead of in a pilot setting,” said Derk Arts, CEO & Founder, Castor. “Decentralized clinical trials offer increased patient engagement, convenience, shorter trial times, and allows for a more diverse representation of patients in studies compared to conventional trials.”

Further accelerated by the COVID-19 pandemic, regulators and trial sponsors emphasize the need for faster, more accessible clinical trials to improve data quality and equitable health outcomes. According to a recent industry survey, an estimated 50% of clinical trials will be hybrid or decentralized by 2024. Castor’s modular DCT platform with integrated EDC allows CROs to streamline traditional approaches and offers a pathway to manage hybrid and DCTs successfully. With increased access to Castor’s professional services team and named customer success manager (CSM), CRO partners receive the technical guidance and operational support to successfully scale their DCT capabilities using a modern, easy-to-learn platform.

“We understand the unique needs of CROs from sales to operations and beyond. We’ve been there as researchers ourselves, and we know when it comes to technology, what works today may not be what is needed tomorrow,” said Andy Lipetz, Senior Director of CRO Partnerships at Castor. “That’s why we built a program dedicated to supporting cross-functional CRO teams and ensuring their success – no matter what.”

Learn more about Castor’s CRO Partnership program here.

About Castor

Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, eConsent, and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide. For more information, visit www.castoredc.com. Follow us on Twitter at @castor.

Contacts

Castor
Dana Perotti, [email protected]

Media
KKH Advisors
Kimberly Ha, [email protected]

Comments closed

Glasgow mini-seminar about the future of FAIR data sharing

November 28th, 2016 by

Castor EDC has recently been approved as a vendor by the Glasgow University NHS R&D department. To celebrate this we are organizing a mini-seminar on ‘’The future of data standardization and sharing in clinical research’’ by our CEO: Derk Arts (MD, PhD). The mini-seminar will take place at the Queen Elizabeth University Hospital, Level 3, Teaching and Learning Centre in Glasgow, UK on the 7th of December from 10:00 to 11:00 a.m. You can register for this event by sending an email to
[email protected].

We believe that sharing collected data from trials has the potential to exponentially increase the efficiency and accuracy of medical research and reduce research waste through repeated trials.

Derk Arts
Derk Arts, MD, PhD

Unfortunately, barriers to do so still exist such as the difficulty to find, access and use previously collected research data sets that were not standardized. 

By incorporating the FAIR principles (Findable, Accessible, Interoperable, and Reusable) in Castor we eliminate these barriers as we allow researchers to expose their data in a way that research data can be shared easily between research projects worldwide.

We will discuss the benefits of FAIR data more in detail while we also go further into the different challenges we face as we move towards the worldwide implementation of FAIR.

The future of data standardization and sharing in clinical research

We strongly believe that the world will experience a major increase in the quality and efficiency of research if we all continue to make data available in environments like the European Open Science Cloud (EOSC).

Castor EDC is convinced that embracing the FAIR principles will help improve healthcare in the long run by ensuring better quality of evidence to base our medical guidelines on.

Finally we will round off by presenting our solution to make capturing FAIR data accessible for every researcher worldwide.

Want to keep up to date?

Subscribe to newsletter!

Oops! We could not locate your form.

No comments yet

Castor named to the 2021 CB Insights Digital Health 150 – List of Most Innovative Digital Health Startups

December 9th, 2021 by

NEW YORK, NY — December 8, 2021 — CB Insights today named Castor, a leading provider of decentralized and hybrid clinical trial solutions, to its third annual Digital Health 150, which showcases the 150 most promising private digital health companies in the world. This year’s Digital Health 150 was unveiled live during CB Insights’ annual Future of Health event. 

The 2021 Digital Health 150 cohort has raised roughly $14.9B in aggregate funding across 522 deals since 2016 and includes startups at various investment stages of development, from early-stage to well-funded unicorns. Companies this year include startups working on data integration & analytics, hybrid remote/ in-person care, digital therapeutics, clinical intelligence, and more.

“This year’s Digital Health 150 is one of our most expansive yet, spotlighting 16 categories including virtual care, clinical trials tech, and workflow automation, as well as adding new categories such as home health tech and computer-aided imaging,” said Brian Lee, SVP of CB Insights’ Intelligence Unit. “Last year’s class has seen more than 20 exits, raised an additional $18.6B in aggregate funding, and announced over 250 partnerships since being recognized, and we’re excited to see the future success of this year’s winners.”

“We’re thrilled that CB Insights has recognized our accomplishments this year, including our efforts supporting all COVID-19 research for the World Health Organization and powering clinical trials for 20+ next-generation digital health companies, alongside fellow finalists MedRhythms, Mahana Therapeutics, and Woebot Health,” said Derk Arts, MD, CEO & Founder, Castor. “The growth and momentum we’re experiencing speak to the value we’re delivering for both pharma, digital health, and researchers across the globe, and are honored to be named to the CB Insights Digital Health 150 ranking this year.”

Through an evidence-based approach, the CB Insights research team selected the Digital Health 150 from a pool of over 11,000 companies, including applicants and nominees. They were chosen based on several factors, including data submitted by the companies, company business models and momentum in the market, and Mosaic scores, CB Insights’ proprietary algorithm that measures the overall health and growth potential of private companies.

Castor offers a leading cloud-based clinical data platform that simplifies the clinical trial process, from recruitment to analysis, for global research. Since 2014, Castor has supported over 8,500 studies across 100+ disease indications and reached over 3 million participants across more than 90 countries. In 2021, Castor closed $45M Series B funding and more than doubled its workforce to 172 employees across 18 countries. Founded on the mission to democratize research across the globe, Castor has been powering ground-breaking COVID-19 research since the start of the pandemic, donating its technology to more than 300 COVID-19 studies across 40 countries.

2021 Digital Health 150 Investment Highlights:

About CB Insights

CB Insights builds software that enables the world’s best companies to discover, understand, and make technology decisions with confidence. By marrying data, expert insights, and work management tools, clients manage their end-to-end technology decision-making process on CB Insights. To learn more, please visit www.cbinsights.com.

About Castor

Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, eConsent, and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide. For more information, visit www.castoredc.com. Follow us on Twitter at @castor.

Contacts

CB Insights
[email protected]

Castor
Kimberly Ha
KKH Advisors
[email protected]

Comments closed

Castor is accelerating global medical device research with decentralized clinical trials platform

November 1st, 2021 by

HOBOKEN, N.J. – November 1, 2021 – Castor, a leading provider of decentralized and hybrid clinical trial solutions,  today announced the acceleration of medical device research & development with its decentralized clinical trial platform to power medical device studies globally. By working with over 150 medical device companies, Castor’s DCT platform is increasing the efficiency of launching medical device clinical trials by ensuring regulatory compliance, optimizing the patient experience, and streamlining the real-time collection of research data.

Innovation within the healthcare industry is on the rise, with medical device manufacturers uniquely positioned to make a global impact on the treatment and prevention of diseases. In line with market growth, the medical device landscape is increasingly complex, as global regulatory bodies enforce stricter regulatory standards for medical device trials. 

For manufacturers, new regulations such as MDR-IVDR and the FDA 21st Century Cures Act are changing the path to approval and placing a greater emphasis on data quality, safety, and transparency.  Leveraging Castor’s globally compliant platform, manufacturers can successfully navigate the regulatory landscape and ensure compliance with an easy-to-use, intuitive technology designed to optimize patient engagement and streamline data collection from multiple sources.  

“Castor offers a truly seamless clinical trial experience for investigators and patients,” said Fernando Correia, MD Ph.D., Chief Medical Officer of Sword Health, a digital musculoskeletal (MSK) care provider. “Fast deployment was critical for us. Castor technology was easy to use and the self-service capability allowed us to deploy a study in just a few weeks. When it came time for our next study, we were able to cut the build time in half by reusing previous study builds.”

Castor’s modern interface and integration capabilities enable medical device manufacturers to achieve compliance and focus on patient outcomes, minimizing the burden of managing multiple technologies, vendors, and processes.  Built for single and multi-site medical device clinical trials, Castor’s modular DCT platform can: 

“For us, it’s important that digital technology is accessible and easy-to-use for patients and researchers. That’s why we are so passionate about delivering a complete self-service solution to help medical device manufacturers navigate their trials,” said Derk Arts, Ph.D., M.D., CEO and Founder of Castor. “We are excited by the opportunity to help medical device companies develop high-engagement, patient-friendly and data integrated clinical workflows that streamline the approval process and ultimately deliver the best products to market.” 

The future of clinical trials is here. Learn more about how you can use Castor’s integrated platform in your next medical device trial at castoredc.com. 

About Castor

Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, consent, and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide. For more information, visit www.castoredc.com. Follow us on Twitter at @castor.

Contacts

Media
Kimberly Ha
KKH Advisors
[email protected] 

 

No comments yet

Trialbee and Castor Partner to Democratize Access and Simplify Enrollment to Clinical Trials Globally

September 20th, 2021 by

Industry leaders to increase patient access to clinical research and scale remote enrollment of participants for trial sponsors to promote increased health equity.

MALMO, Sweden and HOBOKEN, N.J., Sept. 21, 2021 – Trialbee, the leading enrollment performance company, and Castor, a leading provider of decentralized and hybrid clinical trial solutions, today announced a strategic partnership to accelerate patient enrollment, optimize patient engagement, and reduce site burden for clinical trials globally.

Castor and Trialbee’s logical integration allows sponsors to meet enrollment timelines with continuous access to all their study data. Together, the fast-growing companies will expedite patient recruitment and streamline clinical trials through advanced data science and streamlined workflows for patient enrollment, data collection, and engagement. The partnership will diversify patient participation and improve equitable health outcomes for global decentralized and hybrid clinical programs. 

“We are excited to partner with Trialbee to improve patient engagement, as well as optimize patient diversity and study inclusivity with real-time insights around patient demographics across all recruitment channels,” said Derk Arts, M.D., Ph.D., CEO & Founder, Castor. “Our partnership provides sponsors a seamless decentralized and hybrid clinical trial solution to manage all their clinical trial touchpoints and expand inclusivity at a global scale.” 

Recruiting and retaining qualified clinical trial participants is increasingly difficult as clinical study designs become more complex. According to industry estimates, the amount of patient eligibility in clinical trials has increased approximately 150% in the last decade. As a result, life sciences companies demand a patient matching and enrollment platform that can help them better manage the patient’s journey into a clinical trial while optimizing enrollment outcomes. With Trialbee and Castor’s proven integrations, clinical trial sponsors can seamlessly manage all clinical trial touchpoints while ensuring data quality every step of the way.

“Over 70 percent of potential clinical trial participants live more than two hours away from a trial site, increasing the need for greater scale and reach in patient awareness for today’s trial designs,” said Matt Walz, Chief Executive Officer at Trialbee. “Through our combined capabilities, clinical trials can deploy an end-to-end solution to simplify the patient journey, including early introductions to clinical trials, enrollment performance analytics, and remote data capture for decentralized clinical trials.”

About Trialbee

Trialbee is the leading global data and technology platform for patient matching and enrollment in clinical trials. Trialbee Hive™ operationalizes real-world data (RWD) and applies data science to match patients globally. Our enrollment platform simplifies the journey for matched patients to qualify and participate in clinical research. Partnering with Sponsors, CROs, and virtual/decentralized sites, and software providers, Trialbee is achieving patient enrollment goals and driving enhancements in diversity in clinical trial populations. We are the smartest way to match and enroll patients for your clinical trial. For more information, visit http://www.trialbee.com or contact us at [email protected]. 

About Castor

Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, consent, and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide. For more information, visit www.castoredc.com.

Contacts

Doug Weatherhead
Castor
[email protected]

Media
Kimberly Ha
KKH Advisors
[email protected]

Rosina Ferrante
Gregory FCA (for Trialbee)
215-344-2113
[email protected]

 

Comments closed

Castor Appoints Digital Leader Milind Kamkolkar to Board of Directors

November 8th, 2021 by

Industry veteran Milind Kamkolkar joins Castor’s Board of Directors to advance mission of democratizing clinical research by maximizing the impact of clinical data.

HOBOKEN, N.J., November 9, 2021 – Castor, a leading provider of decentralized and hybrid clinical trial solutions, today announced the appointment of industry veteran Milind Kamkolkar to its Board of Directors.

Milind is currently Senior Advisor to Cellarity, a Flagship Pioneering Company, after his tenure as Chief Digital & Data Officer. He brings to Castor more than 20 years of experience in healthcare AI and digital health, from startup, management consulting to Fortune 500 enterprises. As a Board member, Milind will help Castor accelerate its goal of making the world’s research data more accessible, enabling AI-driven clinical trials, and ultimately use actionable data to improve the speed and efficiency of clinical trials.

“The adoption of decentralized clinical trials has seen exponential growth, catalyzing an industry in critical need of modernization,” said Milind. “I was impressed by the leadership, talent and technology at Castor, which complement the hard problems Castor’s platform tackles with technical sophistication. To support the growing clinical research needs of academic centers and life sciences companies, Castor’s technology simplifies the clinical trial process and ‘consumerizes’ new processes for tech-enabled clinical trials. I look forward to contributing my expertise and being a part of Castor’s journey to enable faster, smarter clinical trials.” 

Castor offers a leading cloud-based clinical data platform that simplifies the clinical trial process, from recruitment to analysis, for global research. Castor’s combined Advisory Board & Board of Directors consists of twelve industry leaders that are committed to furthering the company’s mission to make clinical research smarter and faster through technology.

Castor’s Board has been instrumental in fueling Castor’s growth. Since 2014, Castor has supported over 8,500 studies in more than 90 countries. In the last two years, the company more than doubled in size and worked with customers such as the World Health Organization, which used Castor for its Solidarity Trial, landed contracts with over 30 top-tier digital therapeutics companies, and penned enterprise agreements with multiple top 5 pharmaceutical companies.

“We’ve made significant progress in advancing our clinical and technology and practices this year,”  said Derk Arts, PhD, Chief Executive Officer and Founder of Castor. “We are thrilled to have Milind join our Board. His expertise, insights and passion for technology combined with the collective experience of our leadership team and Board, is critical to our ability to operationalize and achieve our vision of democratizing clinical research to maximize the impact of research data for patients worldwide.”

Milind joined Cellarity from Sanofi where he was the first enterprise Chief Data Officer in the pharmaceutical industry. Prior to Sanofi, he was the Head of AI and Data science within the Digital Medicines group at Novartis.

To read more about Castor’s Board of Directors, visit www.castoredc.com/about-us/leadership/.

About Castor

Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, eConsent, and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide. For more information, visit www.castoredc.com.

Contacts

Media
Kimberly Ha
KKH Advisors
[email protected]

Comments closed

AMC and Castor launch partnership

April 5th, 2016 by

We are happy to announce that we are partnering with the Clinical Research Unit (CRU) of the Academic Medical Center (AMC) in Amsterdam, the Netherlands. The joint goal is to enable more AMC researchers to use Castor and at the same time better facilitate these researchers with regards to data management.

AMC & Castor partnerpricing

Within the partnership, the maximum price per study per year for AMC researchers is reduced to €450 per year, regardless of the size of the study. At the same time, the CRU will provide guidance for AMC researchers within Castor itself and proactively present Castor within its research application portfolio next to tools such as OpenClinica and LimeSurvey.

AMC researchers will continue to receive the Castor support they are used to. Additionally the CRU will offer the below services within Castor:

You can read more about these services on the internal CRU website or contact the Head Data Management of the CRU directly. Researchers are of course also welcome to contact us directly.

No comments yet

Try Castor EDC For Yourself

Start designing your own study structure and forms today.

Try For Free
Back to top